International Psoriasis Council

Advancing Knowledge. Improving Care.

Claudia de la Cruz Headshot

Claudia

de la Cruz

,

MD

Clinical Director
Clinica Dermacross
Santiago
,
Chile
Councilor Since: January 1, 2014
IPC Vice President/President-Elect
Dr. Claudia de la Cruz is a dermatologist in Santiago, Chile. She earned her degree at Universidad de Chile and was an Assistant Professor at Pontificia Universidad Católica de Chile between 2005 and 2013. Dr. de la Cruz is the Founder and Director of Clínica Dermacross since 2010 in Santiago. She has served on the Board of Directors of the International Psoriasis Council since 2017 and is a regional coordinator for Latin America for the Global Psoriasis Atlas project. Her focus has been on working for psoriasis in her country through the Chilean Society of Dermatology at the beginning of her career, and then for Latin America, where she has led the IPC Latin American working group together with Ricardo Romiti from Brazil. She is an International Scientific Advisory Board member for PsO Protect. As regional coordinator for Latin America for the Global Psoriasis Atlas, she has focused on collecting information on the incidence of psoriasis in Latin America, helping to build a net of experts throughout the region. She has helped raise awareness and improve access to treatment in the region, evaluating the different barriers to access in Latin America and other underserved areas in the world. She has also worked in education at the IPC, first on the International Fellowship program, which helps train new leaders in the psoriasis field. In 2023, she received the Eikon Gold Award 2023 in health sustainability for her work in psoriasis in Chile. She is currently chair of the IPC Masterclass Steering Committee.
Last Updated:
02/28/2024

Areas of Interest

Epidemiology.

IPC Committees / Groups

Board Vice President/President-Elect, Executive Committee, Latin America Working Group, Regional Development Task Force

Languages Spoken

English, Spanish

Involvement with Other Organization(s)

Meets with the national patient association on a regular basis.

What's New

First-Line Biologics in Psoriasis: Evidence from the BADBIR Cohort Study

In this IPC commentary, Matias Maskin examines evidence from the BADBIR registry demonstrating that first-line biologic therapy in moderate to severe psoriasis leads to faster skin clearance, improved quality of life, and a lower risk of comorbidities. The analysis challenges traditional step-up approaches and supports earlier, patient-centered treatment strategies.

Read More »

Recent Advances in Psoriasis: A Year in Review

In this Take Ten with IPC video, Dr. Leandro Leite discusses the most recent advances in psoriasis over the last year (March 2025 – March 2026). Topics include new guidelines, research, and recent studies.

WATCH NOW

Monday, April 6, 2026